JDRF Research

JDRF funds research that transforms the lives of people with type 1 diabetes (T1D). We want a cure, and we won’t stop until we find one. Along the way, we will continue to drive scientific progress that delivers new treatments and therapies that make day-to-day life with T1D easier, safer and healthier.

How do these research areas transform lives?

JDRF supports the best researchers doing the most promising, cutting-edge science to cure, prevent and treat T1D.

Volunteer for a clinical trial

Become one of the people who help turn promising ideas into proven therapies that change lives.

Learn more

Your support is more critical than ever

JDRF has committed over $1.9 billion to research
JDRF advocates for $150 million
JDRF is currently funding 45 human clinical trials
JDRF is funding research projects in 45 countries

People with T1D would never benefit from JDRF-funded innovations without our donors. The work to create transformational therapies to help people live with T1D cannot—and must not—be allowed to stop because dedicated researchers lack funds. Laboratory studies that are unlocking the mysteries of T1D and accelerating progress toward a cure and prevention must continue. With the generous help of supporters like you, JDRF is pursuing a diversified, dynamic research agenda that is moving us ever closer to a world without T1D.

Donate now

Our commitment to you

If you live with T1D, you spend a lot of time thinking about your blood-sugar levels now and worrying about the complications that T1D may one day bring. You don’t want anyone else you love to ever know the physical, emotional and financial toll this disease takes. You want a cure.

So does JDRF. And we are committed to funding the development of new therapies and treatments to keep people with T1D healthier, longer, until that cure is found. That’s why we invest in multiple therapeutic approaches to cure, prevent and treat T1D. We identify and invest in promising therapies in their early stages, helping researchers pursue innovative ideas and approaches. This investment strategy ensures that the most life-changing breakthroughs can make it through the long research, development and delivery process and get to people living with T1D sooner.

Continue reading

Our Glucose Control and Artificial Pancreas Programs tackle blood-glucose control head on. Managing insulin alone won’t achieve perfect control. So we’re investigating how managing other hormones or repurposing drugs approved for other uses can work with insulin to improve control. Artificial pancreas technology will improve control by automating blood-glucose sensing and insulin delivery. Tighter control reduces complications and eliminates the need to think about blood-sugar levels, insulin dosing and carbohydrate counting.

Beta cell encapsulation therapy holds the promise of eliminating the need for daily insulin treatment for up to 24 months through a small implant. The researchers and partners we support through our Encapsulation Program are testing multiple efforts to perfect cell replacement therapies, including the development of materials to protect the cells and discovery of new replacement cell sources. We think for people with T1D who are on duty all day every day just to stay alive, encapsulation will sure feel like a cure.

We refuse to accept the idea that people with T1D must live in fear of life-threatening diabetic complications. Our Complications Program seeks to better understand how diabetic kidney and eye diseases start so we can stop them in their tracks. Of course, the best way to ward off complications is to protect people from the disease entirely.

Our Prevention Program’s primary goal is to develop a universal childhood vaccine that prevents the autoimmune attack on insulin-producing cells. As we work toward that goal, we’re also pursuing secondary prevention therapies that will prevent people from becoming dependent on insulin therapy once T1D is diagnosed.

Our Restoration Program is attempting to do something that has never been done before—prevent, halt or reverse an autoimmune disease and return normal function of the beta cells.

We know it won’t be easy. It will take time and require a significant financial investment. But we want it all: a biological cure for T1D, transformational treatments that improve lives now and prevention so that future generations never know T1D. JDRF is turning Type One into Type None.

Research News


date site


Designing an On-and-Off Switch for Insulin

November 24, 2015

  Calibr, a biomedical research center sees promising data with its glucose-responsive insulin designs JDRF-supported Calibr, which stands for California Institute for
Read more

Releasing Insulin Like Clockwork

November 19, 2015

Circadian clock controls insulin release, may influence development of diabetes Scientists have shown that disruption of the body’s internal clock system is
Read more

Stimulating Human Beta Cells to Multiply

November 4, 2015

New research identifies a drug target with the potential to restore human beta cells Researchers led by Bryan Laffitte, Ph.D., at the
Read more

Collaboration Leads to Invaluable Discoveries

November 3, 2015

JDRF Encapsulation Consortium   In its early phase, encapsulation research was divided, with experts in different disciplines focused on different aspects of
Read more